$PALI

Baltera Robert Jr. purchased $102K of PALI

Baltera Robert Jr. purchased 50,000 shares of PALISADE BIO, INC. (PALI) at an average of $2.04 ($2.03–$2.05, $0.10M total) across 2 trades over 2026-07-06 to 2026-07-07.

Original reporting
SEC EDGAR · Baltera Robert Jr.
Published Jul 8, 2026, 10:56 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Jul 8, 2026, 11:00 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$PALI
Bullish
medium confidence
Mentioned
$PALI
Relevance
5/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$PALIBullishLow
01

Why it matters

The only new information is the director’s open-market purchase size, price range, and post-transaction holdings; it does not change fundamentals on its own.

02

Market read

Traders may treat the filing as a small sentiment input, but it is unlikely to drive a durable repricing without additional company catalysts.

03

What to watch

The article does not state whether the director’s purchase is part of a broader pattern, nor does it include any accompanying company news that would validate a bullish thesis.

Relevance 5/10Novelty 5/10Timing: today’s SEC Form 4 filing (filed 2026-07-08)

Background

The article is an SEC Form 4 insider transaction disclosure for Palisade Bio, Inc.

Company-level read

Ticker impact

$PALIBullishMedium confidence
Context

SEC Form 4 shows director Baltera Robert Jr. bought 50,000 shares of Palisade Bio at about $2.04 per share in early July.

Expected impact

Likely limited near-term impact; any effect should be small and sentiment-driven.

Evidence & confidence

The filing is a primary-source insider transaction, but the article provides no new operational, clinical, or financial information beyond the purchase details.

Market effects

No sector-level read-across; this is a single-company insider transaction.

None indicated.

None indicated.

Counterpoint

Insider purchases can be routine or driven by liquidity/compensation needs, especially without a 10b5-1 plan.

Key entities

  • Palisade Bio, Inc.

    Company whose director insider purchase is disclosed on Form 4.

  • Baltera Robert Jr.

    Director who purchased 50,000 shares across two trades at about $2.04/share.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$PALILowAI 8/10

Palisade Bio doses first patient in ulcerative colitis trial

Palisade Bio Inc. (PALI) dosed the first patient in its Phase 2b ASCENTRA-UC trial for ulcerative colitis, evaluating PALI-2108. The trial aims to enroll 204 patients and has 29 U.S. sites active, with global expansion ongoing. Topline results are expected in Q4 2027. PALI-2108 is an investigational oral PDE4 inhibitor prodrug. The company also conducts a Phase 2 study for Crohn’s disease.

$PALIMedAI 8/10

Oppenheimer reiterates Palisade Bio stock rating on Crohn’s data

Oppenheimer reiterated an Outperform rating and $8.00 price target on Palisade Bio (NASDAQ:PALI) after additional data from UEG Week. The stock is down 49% over six months but has a Strong Buy consensus and targets ranging from $5 to $25. New tissue analyses showed reduced PDE4D expression and signs of tissue remodeling. Phase 2 trials are ongoing, with data expected in 2H27. Other analysts also reiterated or initiated positive ratings.

$PALIMedAI 8/10

Palisade Bio reports early-stage Crohn’s disease trial results

Palisade Bio (NASDAQ:PALI) reported early-stage trial results for PALI-2108, showing reductions in Crohn's disease activity measures in a small, 5-patient study. The drug demonstrated decreases in disease scores and inflammation markers, with mild adverse events. The company is advancing to Phase 2 studies. Results are preliminary and require further validation.